How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s
Executive Summary
Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.